Pneumonia News and Research

Latest Pneumonia News and Research

Nursing environment linked to improved patient outcomes

Better working conditions and better staffing of nurses can significantly improve the care of patients with serious conditions, according to the latest nurse labor study by the University of Maryland School of Nursing.

28 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Azithromycin holds promise for preventing BPD in Ureaplasma-infected preterm infants

A study performed by University of Kentucky researchers shows promise for the use of azithromycin in treating Ureaplasma-colonized or infected premature infants to prevent bronchopulmonary dysplasia (BPD).

27 Apr 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

PolyMedix defensin-mimetic antibiotic compounds show antimicrobial efficacy against anthrax

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that several of its defensin-mimetic antibiotic compounds have shown antimicrobial efficacy in an animal model against the bacteria that causes anthrax.

26 Apr 2011

Infants with bronchopulmonary dysplasia can benefit from azithromycin therapy

A study performed by University of Kentucky researchers shows promise for the use of azithromycin in treating Ureaplasma-colonized or infected premature infants to prevent bronchopulmonary dysplasia.

26 Apr 2011

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that the U.S. Food and Drug Administration has approved the Company's Supplemental New Drug Application for FUSILEV Injection.

22 Apr 2011

WSU researcher develops potential vaccine for Chlamydia

A Wayne State University School of Medicine researcher has developed a potential first ever vaccine for Chlamydia, the world's most prevalent sexually transmitted disease and the leading cause of new cases of blindness.

21 Apr 2011

Meridian Bioscience second quarter net sales increases 32% to $41.1 million

Meridian Bioscience, Inc., today reported fiscal 2011 second quarter and six months net sales of $41.1 million and $78.3 million, respectively, increases of 32% and 6%, respectively, from the same periods of the prior fiscal year;

21 Apr 2011

Shanghai Pharmaceutical and Pfizer enter MOU to pursue potential business opportunities

Shanghai Pharmaceutical Co. Ltd. and Pfizer Inc. today announced the signing of a memorandum of understanding (MOU) for the companies to jointly pursue potential business opportunities in China.

21 Apr 2011

CMS unveils 2012 hospital Medicare payment proposal

The American Hospital Association responded by saying it was "deeply disappointed" by the proposal, which would cut acute-care hospital payments in the coming year.

21 Apr 2011

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

20 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Nabriva Therapeutics today announced the successful results of a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections.

18 Apr 2011

Drug resistant bug plaguing the meat industry: Study

It has been found that nearly half of the meat and poultry (47 percent) sold in U.S. grocery stores is contaminated with Staphylococcus aureus (“Staph”), a bacteria linked to a wide range of human diseases, and this bacteria is resistant to at least three classes of antibiotics in more than half (52 percent) of contaminated samples. This comes from a nationwide study by the Translational Genomics Research Institute (TGen) published this week in the journal Clinical Infectious Diseases.

17 Apr 2011

Hospital patients with AUDs are at increased risk of developing HAIs: Study

Hospital patients with alcohol use disorders are at an increased risk of developing healthcare-associated infections, which affect 1.7 million patients annually in the United States. HAIs are infections that patients acquire during their hospitalization and that were not present at the time of admission to the hospital.

16 Apr 2011

Patients with COPD can benefit from ICS use

Patients with chronic obstructive pulmonary disease who are hospitalized for pneumonia and treated with inhaled corticosteroids have decreased mortality when compared to those who are not treated with ICS, according to a retrospective analysis of almost 16,000 COPD patients admitted to VA hospitals.

15 Apr 2011

Study finds 47% of meat and poultry samples contaminated with S. aureus

Drug-resistant strains of Staphylococcus aureus, a bacteria linked to a wide range of human diseases, are present in meat and poultry from U.S. grocery stores at unexpectedly high rates, according to a nationwide study by the Translational Genomics Research Institute.

15 Apr 2011

Study identifies Top 10 Cities for Emergency Medicine based on overall mortality rate

A study released today by HealthGrades, the nation's leading, independent source of physician information and hospital quality ratings, found large differences in the risk adjusted mortality rates for patients admitted through the Emergency Department, both by hospital and by market area.

12 Apr 2011